Foundation Funded Research

To date, the GBS|CIDP Foundation has awarded more than $6.8 million in grants meant to advance the knowledge of GBS, CIDP, and variants. Read on to learn about the projects that were chosen based off of recommendations from the Grant Committee of the Global Medical Advisory Board.

Note- grants awarded before 2021 were awarded in amounts of up to $60,000

Congratulations to our 2022 Discovery Grant Awardees

Principal Investigator: Dr. Pietro Emiliano Doneddu, MD

Humanitas Clinical and Research Hospital-IRCCS, Italy

Title of Project: Dissecting the genetic architecture of chronic inflammatory demyelinating

Synopsis: In this study, we aim to characterize the genetic architecture of a large cohort of CIDP patients and healthy controls to evaluate whether specific alleles/haplotypes are implicated in the risk of CIDP, in its clinical and immunological variability,

Principal Investigators: Dr. H.G. (Ruth) Huizinga  and Prof. Bart C. Jacobs

Erasmus MC, University Medical Center Rotterdam, The Netherlands

Title of Project: Pathogenicity of human antibodies cloned from Guillain-Barré syndrome patient              

Synopsis: This project aims to determine the pathogenic potential of human anti-GM1 antibodies. More specifically, we will investigate whether human anti-GM1 antibodies: 1) have different fine specificities and affinities; 2) can induce axonal damage, demyelination or both.

Congratulations to our 2022 Elevation Awardees

Principal Investigators: PD Dr. Moritz Kronlage, MD

University of Heidelberg, Germany

Title of Project: MR-neurography in chronic inflammatory demyelinating polyradiculopathy (CIDP)  

Synopsis: To evaluate the diagnostic accuracy and utility of quantitative magnetic resonance neurography (MRN) for the longitudinal assessment of nerve integrity and therapy response in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

Principal Investigators: Dr. Ioannis Petropoulos

Weill Cornell Medicine Qatar- Qatar Foundation, Qatar,

Title of Project: Corneal Confocal Microscopy: An Objective Imaging Marker for Immune Activation and Neurodegeneration in Guillain Barre Syndrome

Synopsis: To assess the relationship between corneal nerve loss and immune activation with the evolution of clinical disability and outcomes in different subtypes (AIDP, AMAN, MFS, post vaccine) of GBS.

Principal Investigators: Dr Eileen Mc Manus MB BCh BAO BA, MSc.,

Waikato Hospital, New Zealand

Title of Project: The Guillain-Barre Syndrome (GBS) Phenotype in Aotearoa/New Zealand: How Ethnicity, Socioeconomics, and Infection Influence GBS Outcomes

Synopsis: Guillain-Barre syndrome (GBS) is the commonest cause of acute paralysis worldwide    GBS phenotypes are defined based on clinical, electrophysiological, and pathological characteristics [2].  NZ has the highest incidence of GBS in the world and the highest Campylobacteriosis infection rate in the developed world [3,4]. The excess of GBS is entirely attributable to Campylobacteriosis.  Diarrhoea as an antecedent event is strongly linked to more severe GBS [5] and to the acute motor axonal neuropathy (AMAN) phenotype [6] so it would be expected that there would be a higher rate of severe disease and of AMAN in NZ compared to other developed countries. Clinical experience suggests that Māori have a higher incidence of AMAN, the pharyngo-cervico-brachial (PCB) variant and Miller Fisher syndrome (MFS).  Māori also have a worse prognosis. We aim to develop a national registry for GBS in NZ. Currently, there is no GBS registry in NZ.

Principal Investigators: Jean-Philippe Camdessanché PhD, MD,

University Hospital of Saint-Étienne, France

Title of Project: Revealing the autoantigen repertoire of IVIg responders versus nonresponders with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Synopsis: About 20% of patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) do not respond to intravenous immunoglobulins (IVIg). The reason is unknown and predicting markers are lacking. Our recent deep screening found IVIg responders targeting 3 times more antigens than non-responders in a cohort of 22 CIDP patients. Our primary objective is to validate this finding with an independent cohort. Our secondary objective is to systemically analyze the targeted antigen repertoire to find prognostic markers.

2021 Grants

Study: Examining the Role of Microbiota in Inflammatory Peripheral Neuropathies

Award Grantee: Gang Zhang, PhD, University of Texas, Health Sciences Center at Houston

Autoimmune peripheral neuropathies are associated with dysregulated immune responses. The gut microbiome, the bacteria residing in gastrointestinal tract, plays a fundamental role in regulating the host immune system. This proposal will help understand the role of microbiota in pathogenesis of inflammatory demyelinating neuropathies.

Study: Influence of the small chain fatty acid propionic acid on the peripheral immune regulation in the context of chronic in­flammatory demyelinating polyneuropathy (CIDP)

Award Grantee: Anna Lena Fisse, MD, Ruhr University Bochum St. Josef Hospital, Germany

The intestinal immune system and the community of intestinal microbes, the microbiome,determine autoimmune inflammation. Nutrition is a major influence factor on microbiome and supplementation of the fatty acid propionic acid showed positive immunomodulatory effects in diseases like multiple sclerosis. 

The aim of this project is to investigate the immunomodulatory effect of propionic acid in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), who take propionic acid orally for 90 day.

2020 Grants

Inhibition of the terminal complement pathway in EAN with a novel monoclonal antibody targeting C6; Frank Baas, MD, PhD, Prof, Leiden University Medical Center Leiden, The Netherlands

In this project, we will show whether blockade of C6 is an attractive target, as generation of MAC is prevented, but in contrast to C5-inhibition, the C5a-induced pathways remain unaffected.

Nerve Ultrasound for Diagnosis and Prognosis of GBS; Natalia Gonzalez, MD, and Lisa Hobson-Webb, MD, Duke University Medical Center

Delay in Guillain-Barré syndrome (GBS) diagnosis and treatment is associated with higherfrequency of intubation and residual weakness. We have two main objectives for this pilot study: (1) to define peripheral nerve ultrasound (US) measures diagnostic of GBS in the acutesetting and (2) to identify peripheral nerve US biomarkers of GBS prognosis.

Precision medicine in chronic inflammatory neuropathy assessment, Luis Querol MD PhD, Hospital de la Santa Creu i Sant Pau

The aim of this project is to find precise tools that help optimize patientmonitoring in daily clinical practice by using two objective measures of disease activity: a wearablesystem to monitor gait parameters, and serum neurofilament levels, a novel blood biomarker of neuronal damage used in other neurological diseases. If successful, this project will provide better tools to assess disease status and treatment effect and, ultimately, more precision in neurological assessment that help improve patient care and clinical trial outcomes.

Validation of novel biomarkers in acquired inflammatory neuropathies; Professor Michael Lunn, Institute of Neurology, University College London (UCL)

Inflammatory neuropathies are a heterogeneous group of acquired nerve-damaging disorders, which commonly have life-changing implications for sufferers. The most common chronic immune-mediated form, CIDP, has an estimated prevalence of 3 per 100,000 in the United Kingdom1. To resolve these unmet needs, we will identify novel POEMS, GBS and CIDP biomarkers

Lenalidomide in anti-MAG Neuropathy: Phase 1b Study; : Amro Stino, MD, University of Michigan Medical School

We aim to assess the safety profile and maximum tolerated dose of Lenalidomide in anti-MAG neuropathy. Drug efficacy will serve as secondary outcome. Lenalidomide is current standard of care therapy in the treatment of paraproteinemic neuropathies, namely osteosclerotic myeloma (POEMS syndrome), amyloid, and multiple myeloma. Its safety and efficacy in anti-MAG IgM associated demyelinating neuropathy (DADS syndrome) has not been previously explored.

Optimizing (electro) diagnosis in CIDP with machine learning; Camiel Verhamme MD PhD, Amsterdam University Medical Centers, location AMC, Amsterdam, the Netherlands

Despite current diagnostic criteria sets for CIDP, the rate of misdiagnosis is high. In this project, our aim is to develop machine learning (ML) algorithms with improved (electro) diagnostic accuracy for CIDP as compared to current criteria sets.

Proteomics based discovery of disease activity biomarkers in chronic inflammatory demyelinating polyneuropathy, Luuk Wieske MD PhD, Amsterdam University Medical Centers, location AMC, Amsterdam, the Netherlands

Patients suffering from and clinicians treating chronic inflammatory demyelinating polyneuropathy (CIDP) are currently lacking disease activity biomarkers that can provide objective guidance on when to start and stop treatment. Serum proteins may serve as quantitative, responsive and easily obtainable disease activity biomarkers. In this project, our aim is to identify potential disease activity biomarkers by screening a focused blood proteome comprised of 184 proteins related to the nervous system and inflammation

2019 Grants

Pathogenic Th17 cell pathology
: Karissa Gable, Duke University

Evidence from our lab, supported by the medical literature, suggests that T helper cells producing IL-17 (Th17) are important mediators of inflammation in CIDP. We propose
to deeply characterize pathogenic Th17 cell populations in CIDP and determine the effects of Th17 targeted therapy for this disease. Treatments for CIDP have not advanced significantly in many years and new treatment approaches are needed.

Recent Study Update – June 2021

A randomized controlled trial with Rituximab versus placebo in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDPRIT): support for an additional dose of Rituximab after six months of therapy; EDUARDO NOBILE-ORAZIO, Milan University, IRCCS Humanitas

In this study, immunoglobulin therapy will be continued for six month after initial rituximab therapy to allow rituximab to become effective. We originally proposed the same protocol shown to be effective in another immunological disease (rheumatoid arthritis) with rituximab at the dose of 1000 mg intravenously versus placebo on day 1 and 15 after randomization. After reconsidering the results of the rituximab trial in arthritis rheumatoid where its efficacy was significant after 24 weeks but declined at week 48, with proposed an amendment to our Ministry of Health to add a further 1 g dose of rituximab or placebo 6 months after the initial therapy, one week after IVIg suspension (see attached revised protocol). This decision took into account the fact that the primary end-point of the study was the different proportion of patients relapsing within 12 months after therapy initiation. This amendment was approved without further financial support for the additional therapy.

Development of New Biomarkers Using Immune Cells Profiling and T-cell Specific Sequencing; A. JUNG-JOON SUNG, Seoul National University College

In this study, immunoglobulin therapy will be continued for six month after initial rituximab therapy to allow rituximab to become effective. We originally proposed the same protocol shown to be effective in another immunological disease (rheumatoid arthritis) with rituximab at the dose of 1000 mg intravenously versus placebo on day 1 and 15 after randomization. After reconsidering the results of the rituximab trial in arthritis rheumatoid where its efficacy was significant after 24 weeks but declined at week 48, with proposed an amendment to our Ministry of Health to add a further 1 g dose of rituximab or placebo 6 months after the initial therapy, one week after IVIg suspension (see attached revised protocol). This decision took into account the fact that the primary end-point of the study was the different proportion of patients relapsing within 12 months after therapy initiation. This amendment was approved without further financial support for the additional therapy.

Exploring possible role of TGR5 and FXR in autoimmune neuropathy; BETTY SOLIVEN, University of Chicago

There is increasing evidence that diet and gut microbiome regulate the immune function via changes in short chain fatty acids and other metabolites, but also via altering the bile acid composition in the host. These microbially generated secondary bile acids are signaling molecules that interact with multiple host bile acid receptors. For this pilot study, we plan to focus on a G-protein-coupled bile acid receptor 1 (GPBAR1, also known as TGR5), and type 2 nuclear receptor called farnesoid X receptors (FXR), both of which are activated by bile acids and are implicated in the control of the immune system. Both TGR5-selective agonist and FXR-selective agonist have been shown to modulate the function of monocytes and macrophages, but their effects on lymphocytes have not been as well-elucidated. The goal of this pilot study is to investigate our hypothesis that altered expression or function of TGR5 or FXR could contribute to the pathogenesis or disease progression in Guillain Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

Recent Study Update – June 2021

Neuromuscular ultrasound (NMUS) parameters as diagnostic
and prognostic biomarker in chronic inflammatory demyelinating polyneuropathy (CIDP)
; H.G. (RUTH) HUIZINGA & BART C. JACOBS, Erasmus MC, University Medical Center

Antibodies (Abs) to gangliosides play a key role in the pathogenesis of a proportion of patients with Guillain-Barré syndrome (GBS). Although these Abs have been characterized extensively, little is known about the cells that produce these Abs. We have recently demonstrated that plasmablasts, precursors of plasma cells, are elevated in the peripheral blood of one-third of the patients with GBS and that dominant B-cell clones can be identified. Moreover, preliminary data indicate that isolated plasmablasts can be cultured in vitro and secrete anti-ganglioside Abs. Further studies are required to substantiate these findings.

Recent Study Update – June 2021

2018 Grants

Targeting Wallerian-like degeneration in GBS mouse models; Elisabetta Babetto, Ph.D., Research Assistant Professor; The Research Foundation for SUNY on behalf of U. at Buffalo

Axon degeneration accounts for the most debilitating clinical symptoms of Guillain Barré Syndrome (GBS). Our goal is to explore the mechanisms of axon loss in this condition, by testing the hypothesis that axon degeneration in GBS is governed by a defined molecular program amenable for therapeutic intervention. Specifically we will test whether inactivation of proteins, known to dictate axon loss after experimental injury, affords axon terminal protection in murine models of GBS.

Sphingomyelin dosage in GBS/CIDP patients: biomarker validation in a multicenter, prospective study; Luana Benedetti, MD, PhD and  Lucilla Nobbio, PhD; University of Genova, ITALY

The identification of a biomarker specific and sensitive to improve diagnostic accuracy, to monitor disease activity, to stage patients, and to select specific treatments is a prime goal for the GBS/CIDP Community. Due to the encouraging results we obtained by dosing SM levels in the CSF of patients affected by GBS and CIDP, we propose the present study whose major significance is to validate our results on a sizeable and carefully selected number of patients.

(IGOS) in Switzerland: a deeper look into HEV-induced GBS; Paolo Ripellino, MD, Neurologist; Neurocenter of Southern Switzerland

This study will increase the amount of clinical and prognostic data of the IGOS consortium with the inclusion of patients from an important area located in the middle of Europe. The high quality of the Swiss health care system will allow researchers to obtain accurate data. The systematic collection of acute phase samples in a biobank will be fundamental for future international, cooperative studies. The subproject about the role of HEV is innovative because – although so far neglected – HEV is an increasing, preventable (by appropriate cooking and blood donors testing) disease and this infection is associated to GBS.

Disease-specific Biomarkers In Inflammatory Neuropathies; Luis Querol MD PhD; Hospital de la Santa Creu i Sant Pau, Barcelona

Inflammatory neuropathies (IN) are disorders in which disease-specific biomarkers are not required or diagnostic purposes, leading to disease heterogeneity. We discovered the association of anti-contactin-1 antibodies to a specific CIDP subset using an unbiased approach. This strategy has also proven effective in antibodies against NF155 and nodal neurofascins in CIDP, in which our group has also played a central role. The discovery of paranodal antibodies hasboosted translational research in the field, including the description of specific pathology, genetic background (DRB1*15 association with NF155 antibodies), response to treatment and animal models, supporting the idea that the classification of IN according to disease-specific biomarkers would make IN research and care more efficient.

 Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in CIDP (OPTIC trial);  Dr Laura Zambreanu, MD, MRCP; National Hospital for Neurology and Neurosurgery, UK

 Most CIDP patients are treated with regular intravenous immunoglobulin (IVIg) because of fast improvement and rare adverse events, but IVIg is expensive. Corticosteroid treatment is associated with longer time to improvement and more side effects, but may lead to long-term remission1,2. We intend to participate in a multicentre, randomized, double-blind, placebo-controlled superiority trial in patients with active CIDP. The primary objective is to assess whether combining IVIg and intravenous methylprednisolone (IVMP) leads to more frequent long-term remission in CIDP compared to IVIg alone. Patients will be recruited in the Netherlands and the UK.

2017 Grants

Enhance peripheral nerve repair by modulating macrophage subsets:(Gang Zhang, PhD Assistant Professor of Neurology University of Texas, Health Sciences Center at Houston)

Synopsis: Autoimmune neuropathies consist of a group of peripheral nerve disorders associated with dysregulation of adaptive and innate immune responses. Among these disorders, Guillain-Barré syndrome (GBS) is one of the most common causes of acute flaccid paralysis worldwide. Two immune modulating therapies, namely, Intravenous immunoglobulin (IVIg) and plasma exchange, have been developed to treat GBS. However, there are many disadvantages including high cost, supply shortages, and multiple side effects that are usually associated with high dose and long infusion time of IVIg. Therefore, new therapeutic strategies that can limit the nerve injury during the acute phase of the disease and enhance repair during recovery period are highly desirable. It is in this context we propose a novel therapeutic strategy of modulating macrophage polarization (promote M2 polarization) for treating GBS. Macrophages are central regulators of inflammation.

Probing the role of skin biopsy in CIDP nodo-paranodopathies: (Raffaella Lombardi,1 Jerome Devaux,2 Andrea Cortese,3 Giuseppe Lauria1)

Synopsis: CIDP is a heterogeneous pathology that critically lacks of diagnostic and prognostic biomarkers. The recent identification of IgG4 anti-neurofascin 155 (Nfasc155) or anti-contactin 1 (CNTN1) antibodies in a subset of patients has widened the spectrum of CIDP phenotypes. These patients how disabling tremor, poor response to intravenous immunoglobulin, and distal and sensory disturbances. Cell-adhesion molecule Nfasc155 and CNTN1 are expressed on the paranode, and play key roles on sodium channel clustering and glia-axon interactions. Our preliminary results on skin biopsies from three IgG4 Nfasc155-positive CIDP patients revealed complete loss of Nfasc155 staining at the paranodes, asymmetrical paranodes and widening of the nodes of dermal myelinated nerve fibers. One IgG4 CNTN1-positive CIDP patient showed abnormal nodal/paranodal immunostaining with different features as compared with IgG4 Nfasc155-positive patients suggesting specific changes.

Flavivirus and arbovirus associated GBS in South East Asia: (Umapathi Thirugnanam, Senior Consultant Neurologist, National Neuroscience)

Synopsis:  A number of antecedent infections are associated with Guillain-Barré syndrome (GBS). Recently, symptomatic and asymptomatic Zika virus (ZIKV) infection has been shown to trigger GBS. In the Southern hemisphere the burden of flavi and other mosquito-borne arbovirus infections such as dengue, chikungunya and Japanese encephalitis is considerable. Even in a small, developed country like Singapore, dengue infections can exceed 20,000 a year. Symptomatic dengue has been documented to antecede GBS. Recently we reported that asymptomatic dengue could also trigger GBS. In parts of South East Asia, GBS cases increase after rainy season when mosquitos breed and dengue infections are common. The anecdotal experience of doctors working in these region suggests that diarrhea associated GBS is infrequent. The actual burden of dengue and other arbovirus, including ZikV, associated GBS is uncertain. The ZikV strain responsible for the current epidemic is Asian, described in 1960-70s in South East Asia. It is conceivable that ZikV isendemic in this region. The serological response to secondary infections in patients previously infected with dengue or other flavivirus may also impact on the propensity for these viruses to induce dysimmunity. These questions on immunopathology of flavivirus and arbovirus related GBS are particularly pertinent as the search for vaccines is intensified and large scale vaccinations are expected shortly.

2016 Grants

Effect of Anti-Contactin-1 Antibodies on DRG Neuron: (Dr. Kathrin Doppler MD, Prof. Dr. Claudia Sommer University Hospital Würzburg)

Synopsis: Antibodies against the paranodal (excitable area of the axon in between the myelinated sections) protein contactin-1 have been reported in a subgroup of patients with CIDP who have tremor and an unsteady gait. Binding of autoantibodies is proposed to lead to impaired nerve conduction. Contactin-1 is also expressed by sensory neurons of the dorsal root ganglia (DRG). It is proposed by the applicant that Ab binding to the DRG causes sensory ataxia (unsteady gait) in patients. Anti-contactin-1 Ab decreases the density of sodium channels on DRG neurons. They therefore hypothesize that binding of anti-contactin-1 to DRG neurons affects the physiology of voltage-gated sodium channels and thus impairs neuronal function. They will determine the effect of anti-contactin-1 Ab on the function of these sodium channels by patch clamp recordings of living cultured mouse DRG neurons after incubation with patients’ or control IgG prepared from Therapeutic plasma exchange material of patients and controls. Ab binding will be confirmed with a cytochrome labeled second antibody.

Development of a Tolerogenic vaccination for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): (Cristoforo Comi, MD, PhD. Assistant Professor of Neurology Department of Translational Medicine, University of Piemonte Orientale)

Synopsis: CIDP is an autoimmune disease in which peripheral nerve injury reflects both antibody (Ab) and cell-mediated immune responses against peripheral nerve components or antigens (Ags). Candidate Ags include myelin proteins used to induce experimental autoimmune neuritis (EAN) and nodal/paranodal proteins including contactin-1 and neurofascin. Better knowledge of the spectrum of autoAgs is crucial to develop new specific therapies, such as tolerogenic (or “inverse”) vaccination to turn off the specific immune response. This lab previously developed a vaccine to Experimental Allergic Encephalomyelitis by using nanoparticles encapsulating both auto Ags and immunomodulatory substances that inhibited experimental autoimmune encephalomyelitis

Loss of Schwann cell plasticity in CIDP: A central role for GM-CSF: (Helmar C. Lehmann, MD Department of Neurology University Hospital of Cologne Kerpener Strasse)

Synopsis: Current available therapies in CIDP are aimed to reduce inflammation in affected nerve fibers. However there is no treatment available to enhance regeneration once nerves are injured.   We observed in preliminary experiments that Schwann cells fail to support regeneration of injured nerves when they are exposed to blood components of CIDP patients. Preliminary studies showed a significantly “low expression of cytokine GM-CSF” that might be responsible for the incomplete clinical recovery seen in many CIDP patients. We propose a set of experiments to characterize the pro-regenerative potential of GM-CSF in more detail and to assess GM-CSF as putative biomarker in CIDP. The medium-term goal is to develop a novel treatment strategy to enhance nerve regeneration in CIDP.

Defining the contribution of B cells to CIDP pathogenesis: (Dr. Kevin O’Connor PhD. Assistant Professor of Neurology, Human and Translational Immunology Program Yale School of Medicine)

Synopsis: Several lines of evidence implicate cellular and humeral factors, either acting independently or in concert, in CIDP pathogenesis. Newly identified proteins in the paranodal region (neurofascin-155, contactin-1 and caspr-1) have recently emerged as antibody targets in about 10% of CIDP patients. However the precise contribution of B cells and autoantibodies to the pathogenic mechanisms remains to be defined. CIDP patients with autoantibodies against these surface paranodal proteins exhibit distinct clinical symptoms; moreover, patients with such antibodies seem to respond to CD20-targeted (B cell elimination) treatment. We propose a pilot study of four CIDP patients positive for autoantibodies recognizing paranodal antigens, four CIDP patients with no detectable levels of these autoantibodies and a group of age-matched healthy controls.

Analysis of antibody responses against nodal/paranodal antigens in an Austrian cohort of patients with Guillain-Barré Syndrome: (Julia Wanschitz, Department of Neurology, Medical University of Innsbruck, Austria)

Synopsis: Nodal and paranodal proteins have been identified as novel targets for antibody responses in Guillain-Barré Syndrome (GBS). The frequency of these antibodies and their association with distinct subtypes of GBS, however, remain poorly investigated. They will 1) to analyze the frequency of antibody responses against characterized antigens Contactin1, Neurofascin155, and CASPR2 in an Austrian cohort of GBS patients and 2) to identify novel nodal/paranodal antigens in GBS.

An Italian Multicenter Network for the diagnosis and therapy of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and of its variants Proponent: ( Eduardo Nobile-Orazio Neurology, Department of Medical Biotechnology and Translational Medicine, Milan University

Synopsis: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a chronic and disabling   disease of the peripheral disease of the nervous system that often improve with immune therapy. Several variants have been included under this term but their relation to CIDP is not established considering their sometime different response to therapy. The objective of this study is to determine the frequency and characteristic of these variants, the diagnostic criteria used for their diagnosis, their possible evolution into typical CIDP, the association with specific antibodies, and their response to therapy

2015 Grants

Molecular Structural Basis of Autoantibody Recognition in GBS (Kenneth KS. Ng, PhD, University of Calgary, Alberta, Canada)

Background: Glycolipids are part of cell membranes, and serve as markers or binding sites for molecules such as antibodies. Gangliosides are a type of glycolipid found in the membranes of nerve cells. In GBS, autoantibodies (antibodies against ourselves) attach to gangliosides which in turn impacts neuronal repair mechanisms.Goal: to understand how GBS-specific autoantibodies recognize (attach to) glycolipids in a manner that ultimately leads to the development of the disease. Methods: Determining the structures of antibody-ganglioside complexes using x-ray crystallography will help researchers understand how GBS-specific antibodies attach to gangliosides. This will allow for the design of antibody-blocking inhibitors (things that could block the binding of antibodies to gangliosides) which will disrupt the progression of GBS and prevent nerve damage.

Identifying therapeutic targets in GBS models (Rhona McGonigal, PhD; Neuroimmunology Research Group
Institute of Infection, Immunity and Inflammation University of Glasgow; Glasgow, Scotland) 

Background: Current treatments for GBS are standard and essentially treat all cases in a similar, non-specific way. However, this ignores the fact that there are different triggers and mechanisms for GBS, and that not every case proceeds in the same way. Goal: To create a relevant animal model (mice) that will help us better understand how, when, why, and what causes myelin to degenerate, ultimately revealing potential sites for targeted, specific treatments that will improve patient outcome and reduce the socio-economic burden of the disease. Methods: creating an animal model will help to understand the signaling pathway that leads to GBS. This experiment will use genetically modified glycolipid antigen expression (things that trigger autoantibodies to form and attack the body) to study the pathways and signaling related to myelin degeneration and repair. Preliminary data has already indicated that different outcomes are associated with different antigen (antibody triggers) expression, which supports the idea that different cases of GBS could benefit from different therapies and treatments.

The clinical and functional significance of autoimmune responses to nodal antigens in patients with inflammatory demyelinating neuropathies. (Emily Mathey, Matthew Kiernan, Cindy Lin, Susanna Park, John Pollard and Patricia Armati.; Neuroinflammation Laboratory, Brain & Mind Research Institute, University of Sydney, Australia)

Background: The myelin coating in neurons is interrupted by small gaps, called nodes of Ranvier, which help propel electrical charges down a nerve. Recent GBS and CIDP research has focused on autoantibodies directed towards these nodes, but it is unclear if these antibodies cause disease or represent a secondary effect unrelated to the emergence of the disease. Goal: To examine the significance of antigen (things that trigger antibody formation) targets on these nodes and to correlate them to immunological, neurophysiological, and clinical responses, and to help determine need for IVIg or other therapies. Methods: to identify target antigens by developing cell lines required to screen for these antigens. Patients will be followed over 4 years to determine response to treatment and outcome.

Biobanking for Guillain-Barré syndrome: in search of biomarkers for clinical course and outcome. ( Bart C. Jacobs
Departments of Neurology and Immunology Erasmus MC, University Medical Center Rotterdam, Netherlands) 

Background: The International GBS Outcome Study (IGOS) is a prospective cohort study aiming to identify biomarkers to monitor disease activity and predict clinical course and outcome in individual patients with GBS worldwide. Biomaterials are currently collected and stored in >100 centers in 18 countries from at least 1000 patients with GBS followed over 1-3 years. Goal: To develop a centralized biobank in order to better research these biomarkers and exploit the full potential of IGOS. From this biobank samples will be distributed to sites all over the world for research projects on biomarkers. Methods: Transport DNA and serum samples currently stored at local sites to the central storage facilities in Rotterdam and Glasgow and distribute these biosamples to research centers.

ICOS, Predictors of Treatment Response (the committee expressed limited interest feeling that monetary support was not required to do this study)

Background: This is essentially the same study as IGOS, but for CIDP. There is no web-based registry and bio databank for CIDP patients currently. Goal: To define the diversity of CIDP and biomarkers of disease activity, and to identify predictors of treatment response and how chronic the disease will be. Methods: Using both new onset and established patients, clinical and electrophysiological features will be collected at baseline and during a follow-up period of at least 3 years.

2014 Grants

“PARANODAL AUTOIMMUNITY IN CIDP: DIAGNOSTIC AND THERAPEUTIC VALUE” Dr.  Isabel ILLA; Catedràtica Neurologia U.A.B., Unitat Patologia Neuromuscular, Servei Neurologia Hospital Santa Creu i Sant Pau

A subset of CIDP patients with a clinically distinct presentation have a specific class of antibodies of the IgG4 isotype against proteins at the node of Ranvier, a specialized portion of the nerve between myelinated segments including the paranodeal region. This area of the nerve facilitates impulse propagation. Damage to the region results in weakness and sensory loss. Antibodies to proteins at the paranode are contactin-1 and neurofascin 155 in a limited number of CIDP patients present with distinct clinical features including tremor but do not respond to standard treatment with IVIG or corticosteroids. The immunopathological mechanisms leading to the production of anti-contactin 1 (CNTN1) and anti-neurofascin 155 (NF155) antibodies and to nerve damage in CIDP patients are unknown. The 3 main objectives are as follows.

  • First, to expand the number of of CIDP patients with antibodies against paranodal proteins. Regarding this objective we have been able to identify 4 new patients (2 anti-contactin-1 and 2 anti-NF155) positive through alliances with other centers in Spain and Europe. Alliances with other centers will try to confirm the clinical phenotypes described in our original work.
  • The second objective aimed to identify specific pathological patterns in CIDP patients’ skin biopsies. The work on this objective has not started yet. We will try to identify more patients with antibodies against paranodal structures and then proceed
  • The third objective focused on study of the immunological environment leading to IgG4 anti-CNTN1 – NF155 production, in particular with regard the numbers of regulatory B cells. We have started to set-up the technique for B-reg identification and ran several controls. Once the technique is perfected we’ll start to test neuropathy patients.

Potential outcomes and implications: The confirmation of the association of anti-CNTN1 –NF155 antibodies with specific clinical features in larger cohorts could provide clinically relevant findings for diagnosis. The description of specific immunopathological findings in these patients could identify a subset of patients that would respond B-cell depleting therapies.


The project involves two studies with the following objectives. (1) Participation in International Guillain-Barré Syndrome (GBS) Outcome Study (IGOS) to define the clinical course and outcome of the Guillain-Barré syndrome (GBS) in developing countries and to identify the preceding infections and other factors that influence outcome, and (2) To investigate the safety of small volume plasma exchange (SVPE) as a new treatment for patients with GBS in Bangladesh and other low-income developing countries where the expense of machines used in Plasma Exchange and the cost of intravenous immune globulin precludes their use.

Objective 2: Investigate the safety of small volume plasma exchange (SVPE) in patients with GBS in Bangladesh.

A therapeutic study with SVPE, will be set up to determine the feasibility and safety in the treatment of GBS in low-income countries for patients who cannot afford the currently proven effective but very expensive treatment options as e.g. plasma exchange and intravenous immunoglobulins. SVPE is based on the same presumptions as plasma exchange: removal of soluble neurotoxic factors from the blood, including antibodies and complement factors. We developed the protocol on SVPE, and presented a draft version in INC/PNS meeting 2014 held in Dusseldorf, Germany. We took opinion from international experts for this invasive study and adopted in the current protocol. In addition we further improved the protocol in collaboration with experts in infection prevention, intensive care of neurological patients and biostatisticians from Erasmus MC who are experienced in conducting intervention studies in patients with GBS. The protocol for the study has recently been finalized and will now be submitted for local IRB approval. The next two IRB meetings are scheduled in the first week of March and April. We aim to start the first patient inclusions before the summer 2015, pending on the IRB recommendations and approval. Enclosed goes the prefinal study protocol to be submitted soon.


This Project comprises of the following objectives: (1) To identify new biomarkers for predicting poor outcome in GBS focusing on new preceding infections and anti-neural antibodies, (2) to develop new prognostic models for GBS to predict outcome based on the previously collected data and (3) to develop an outcome measure to define the long-term outcome of GBS in low-income countries.


Twenty percent of GBS patients have a delayed clinical recovery and may have significant disability at the end of a year reflect in part underlying damage to the peripheral nerve axon. The presence of antibodies to sugar containing lipid molecules called gangliosides in myelin membrane are reported to influence the nerve repair. Knowledge of the molecular mechanisms controlling nerve repair could potentialy identify new therapies. Many agents including ganglioside antibodies delay axon regeneration by activation of a common pathway to halt axon regeneration and reinnervation of muscle needed to re-establish motor function in patients. Aim 1.- To demonstrate the role of collapsing response mediator protein-2 (CRMP-2) as a downstream effector of RhoA/ROCK pathway mediating microtubule destabilization at growth cones (GC) by using a site-specific phosphorylation/inactivation mutant of CRMP-2 at residue T555 (negatively regulated by ROCK). Aim 2.- To study the potential therapeutic benefit of modulating the RhoA/ROCK signaling pathway in an in vivo model of axon regeneration using the ROCK inhibitor Y-27632. We experienced some delay in the large scale production of mAb 1B7 (several mg of Ab are required for each animal). For this reason aim 2 will be carry out during this month.

REGULATORY B CELLS IN ANIMAL MODELS OF CIDP, Betty Soliven Neurology Department University of Chicago

We propose that impaired mechanisms mediated by these Bregs contribute to the persistence or progression of CIDP. This hyposthesis will be examined in SAP, which mimics the progressive form of human CIDP. The goal of this pilot project is to examine whether B7-2 KO NOD mice exhibit altered numbers or impaired function of Breg1 and B10 cells, and if so, find ways to correct these abnormalities. Amongst the agents to be tested in vitro include granulocyte macrophage colony stimulating factor (GM-CSF) and retinoic acid, both involved in regulating immune tolerance. Flow cytometry, thymidine proliferation, and intracellular cytokine staining will be used in these studies to determine the presence and absence of the Bregs. We will determine if SAP can be suppressed or prevented by infusions of sorted Breg1. Clinical assessment, grip strength measurements, sciatic nerve conduction studies and nerve pathology studies will be performed. These studies will provide insight into mechanisms that regulate the development of CIDP, and may potentially lead to novel therapeutic strategies to increase numbers of Bregs in human CIDP.

2013 Grants


Hubert P. Endtz, MD PhD1,2,*, Zhahir Islam, PhD1, MD1, Deen Mohammed, MD PhD3, Bart C. Jacobs, MD PhD4 ,1International Centre for Diarrheal Disease Research, Dhaka, Bangladesh;
2Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands;
3National Institute of Neuroscience, Dhaka, Bangladesh and Dhaka Medical College Hospital;
4Neurology and Immunology, Erasmus MC, Rotterdam, The Netherlands;

ObjectivesThe proposed project involves two objectives: (1) to define the clinical course and outcome of Guillain-Barré syndrome (GBS) in low-income countries and to identify the preceding infections and other factors that influence outcome, and (2) to investigate the safety of small volume plasma exchange (SVPE) in patients with GBS in Bangladesh. Methods. (1) Three hospitals in Dhaka, Bangladesh will participate in the International GBS Outcome Study (IGOS), which will provide a website and infrastructure for standardized measurement of outcome. (2) Twenty patients with severe GBS who are unable to walk will be included in a phase II study investigating the safety of small volume Plasma exchange, using the IGOS database for data registry

ALPHA-1-ANTITRYPSIN AS A NOVEL THERAPY FOR CIDP; Maureen A. Su, MD, Assistant ProfessorDepartment of Pediatrics and Microbiology/Immunology, University of North Carolina at Chapel Hill

Current treatments for CIDP do not work optimally for many patients. Alpha-1-antitrypsin (A1AT), a circulating serine protease inhibitor, re- verses certain autoimmune diseases by exerting potent immunomodulatory effects. Whether A1AT is effective in reversing autoimmune peripheral neuropathy is unknown. It may be able to reverse autoimmune peripheral neuropathy by increasing the frequency of suppressive regulatory T cells (Tregs). In this proposal, a new CIDP mouse model developed by our group to test whether A1AT might be a potential new treatment option for CIDP. Since A1AT is safe and approved for replacement therapy in humans, findings from this study have the potential for immediate translation to CIDP patients.

Future directions: Our ultimate goal is to develop a new strategy for treating patients diagnosed with CIDP. To date, both alpha-1 antitrypsin and clodronate liposome treatment appear to prevent neuropathy before disease onset, but do not have efficacy in reversing (treating) disease. Given the distinct mechanisms by which alpha-1-antitrypsin and clodronate function to dampen autoimmunity, we hypothesize that alpha-1 antitrypsin and clodronate liposome treatment may function in combination to reverse autoimmune peripheral neuropathy. We plan to test this hypothesis in the next stages of this project. We plan to write up our findings in the next year and will utilize this data generated with funding from the GBS/CIDP Foundation to apply for an NIH NINDS R01 grant.

Project Title: LENTIVIRUS TRANSDUCED DENDRITIC CELLS EXPRESSING VIP FOR THE TREATMENT OF CIDP; Jerry R Mendell, MD, Curran-Peters Endowed Chair in Pediatric Research Professor of Pediatrics and Neurology, Children’s Hospital

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated demyelinating disorder. 35-40 % CIDP patients do not respond well to conventional treatments [intravenous immunoglobulin (IVIg), plasma exchange and corticosteroids] and require an on-going multi-drug regimen. In this study, we used spontaneous autoimmune peripheral polyneuropathy (SAPP) model in B7-2 knockout non-obese diabetic (NOD) mice as an animal model for CIDP which mimics a progressive and unremitting course of CIDP. Auto-reactive T-cells and auto-antibodies directed against myelin protein zero (P0) were detected in SAPP mice. Tolerogenic dendritic cells (tDCs) were shown to home to inflamed and lymphoid tissues to suppress autoimmune responses by reducing the inflammation and priming naïve T cells to be regulatory cells (Tregs). Vasoactive intestinal peptide (VIP) plays an active role in generation of tDCs from bone marrow cells. VIP expressing DCs, transduced with lentivirus vectors (LV-VIP-DCs) exerted a sustained clinical effect on EAE model. Specific aims; We hypostasized that systemic administration of LV-VIP-DCs will suppress immunogenic responses against the myelin protein P0 and prevent nerve fiber demyelination in SAPP mice. Our specific aims included: Aim 1. SAPP mice will be treated at week 16 with LV VIP DCs to suppress inflammation in the nerve and generate “myelin P0 antigen specific Tregs” to inhibit auto-reactive T cell responses directed against myelin. The rationale for treatment at 16 weeks is to provide a disease modifying effect. Aim 2. SAPP mice will be treated at week 20 with LV VIP DCs. These mice will have an easily identified clinical neuropathy as well as an inflammatory process in the nerve. The goal is reversal or rescue of the ongoing neuropathy

Data Published in the meetings and peer-reviewed journals– Our the scientific abstract, number 2007, entitled Treatment Of Experimental CIDP Using Lentivirus Transduced Dendritic Cells Expressing VIP, was accepted for dual oral presentation at the American Academy of Neurology 66th Annual Meeting, April 26 to May 3, 2014 at the Pennsylvania Convention Center in Philadelphia, PA.

2012 Grants

Comparing sialylated IgG and Fc fragments with IVIG in an anti-ganglioside antibody induced neuropathy model of GBS; Dr C.A. Massaad The University of Texas Health Science Center, Houston, TX

High doses of Intravenous immunoglobulin (IVIG), requiring infusion over several days, are widely used for the treatment of Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Recent studies indicate that autoantibody- and Fcγ receptor-mediated inflammatory cascade, is abrogated by a sialic acid-enriched minor populations present in commercial IVIG preparations. We have recently established that Fcγ receptor activation is critically involved in neural injury in a mouse model of GBS. In this study, we investigated the effects of sialic acid-enriched IVIG (seIVIG) and compared them with whole/native IVIG (nIVIG) and sialic acid-deficient IVIG (sdIVIG) in an established model of nerve repair in which anti-ganglioside antibodies significantly inhibit axon regeneration. We used lectin affinity-chromatography to generate various IVIG fractions and used them in a passive transfer model of anti-ganglioside antibody-mediated inhibition of axon regeneration. Behavioral, electrophysiological, and morphological studies showed beneficial effects of nIVIG and seIVIG on abrogating the adverse effects of anti-ganglioside antibodies on nerve repair. Notably, seIVIG was equally efficacious at a dose tenfold lower than the nIVIG. sdIVIG was ineffective in modulating anti-glycan antibody-mediated inhibition of nerve repair. Further, our lectin chromatographic studies indicate that various commercial IVIG preparations have up to 2-fold variation in seIVIG content. Our findings have translational implications as smaller amounts of IVIG and shorter infusion times are preferable because common side effects of IVIG relate with rate of infusion and amount administered. Shorter infusion times are likely to increase patient acceptance of repeated IVIG infusions necessary for the treatment of chronic immune neuropathies such as CIDP.

CD4+CD25+ regulatory T cells as Potential Biomarkers of Pathogenesis and Response in Therapy in CIDP Patients; Dr E.P. Simpson Methodist Neurological Institute, Houston, TX

No work was completed on this project and the monies are being refunded.

Tregitopes: A Novel Immunomodulatory Therapy for CIDP; Dr. L. Cousens EpiVax, Inc., Providence, RI

Regulatory T cells (Treg) suppress inflammation and therefore are critically important for resolution of autoimmune chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP treatment focuses on inhibiting inflammation, and thus demyelination and secondary axonal loss. IVIG, an approved CIDP therapy, induces expansion of Treg in a number of human diseases and animal models. The efficacy of IVIG has been demonstrated in clinical trials, although the precise mechanism of action by which IVIG exerts its immunomodulatory effects is not clearly understood. Alternative therapies are needed, as IVIG cost and availability remain major barriers to meeting the medical needs of CIDP patients. In recent work, EpiVax has identified one trigger for Treg expansion, natural T regulatory cell epitopes (Tregitopes) contained in immunoglobulin G, and therefore in IVIG. Tregitope peptides have now been shown to replicate the effects of IVIG in a number of in vitro and in vivo models. The IVIG-like effects of Tregitopes have been validated by independent laboratories in mouse models of Type-1 Diabetes, multiple sclerosis, transplant rejection, allergy and asthma, thus confirming our primary observations. We propose Tregitopes as a potential substitute for IVIG in the treatment of certain autoimmune diseases. We reason that CIDP will also respond to Tregitope immune-modulating therapy, and that this may prove to be a more specific and accessible therapy relative to IVIG. We are studying the therapeutic application of Tregitopes to ameliorate disease in the mouse model of CIDP disease. These studies will provide critical insight into basic mechanisms by which Tregitopes engage Treg to induce tolerance and will define key parameters for Tregitope therapy in CIDP.

2011 Grants

The role of osteopontin and anti-osteopontin antibodies in CIDP; Dr. C. Como University of Eastern Piedmont Amedeo Avogadro, Italy

Several studies have explored the role of OPN in autoimmune diseases, but little is known about its role in inflammatory polyneuropathies. A role is suggested by the finding that OPN is constitutively expressed in the PNS and up-regulated in rat experimental autoimmune neuritis13. It is noteworthy that OPN can inhibit T cell apoptosis14, that we previously showed to be defective in CIDP15.Given these premises, the main objectives of this project were: a) to explore the role of OPN and anti-OPN auto-antibodies in CIDP; b) to further characterize apoptotic pathways involved in T cell survival in CIDP. Specific aims were the following: 1) To evaluate the levels of OPN and anti-OPN auto-antibodies in CIDP and GBS and assess their correlations with disease status (relapse, remission, chronic phase). 2) To type the OPN gene haplotypes and analyze other genes involved in T cell apoptosis in CIDP and GBS patients.

Examining antagonistic/synergistic effects of IVIg and erythropoietin (EPO) in a model of autoimmune neuropathy; Dr G. Zhang The University of Texas Medical School of Houston, TX

OBJECTIVE: To examine the potential antagonistic/synergistic effects of IVIg and EPO in preclinical models of anti-ganglioside antibody (Ab)-mediated neuropathy and inhibition of axon regeneration. BACKGROUND: Anti-ganglioside antibodies (Abs) are commonly present in patients with Guillain-Barré syndrome (GBS). We and others have shown that intravenous immunoglobulins (IVIg) can prevent anti-ganglioside Abs mediated complement dependent nerve cell/fiber injury. Our recent studies suggest that erythropoietin (EPO) enhances nerve repair in preclinical models of GBS. IVIg is now the standard treatment for GBS and a new trial to examine the efficacy of EPO in GBS would have to be done as add on therapy with IVIg. It is necessary to demonstrate that EPO and IVIg do not have antagonistic effects. It would also be important to know whether these two medications have synergistic effects to design an effective administration schedule in patients with GBS. DESIGH/METHODS: Previously published preclinical models of autoimmune neuropathy mediated by anti-ganlioside Ab were used to examine the potential antagonistic/synergistic effects of IVIg and EPO. RESULTS: Our results show that individual treatments with either IVIg or EPO provide significant protection, i.e., postpone the anti-ganglioside Ab- and complement-mediated neural injury to the neurites and neuronal cell body, in the neurocytotoxicity assays. Notably, no antagonistic effects were seen with the combined use of IVIg and EPO in these assays. Our data suggest that EPO and IVIg have synergistic effects in protecting neuronal cells from this anti-ganglioside Ab-mediated complement-dependent injury. CONCLUSTIONS: Our results support the conclusion that EPO can be useful add-on therapy to the current standard IVIg treatment for GBS. This novel combination therapy can be potentially beneficial for protecting nerve from injury during the acute phase and enhancing nerve repair in the recovery period in GBS patients.

Acknowledgements: These studies were supported by GBS/CIDP Foundation and NIH/NINDS (NS42888 and NS54962).

Implementation of the International Guillain-Barre Syndrome Outcome Study (IGOS); Dr B.C. Jacobs Erasmus MC, The Netherlands

The International GBS Outcome Study (IGOS) is a worldwide prospective cohort study conducted by the International Neuropathy Consortium (INC) that aims to identify the clinical and biological determinants of disease progression and recovery in GBS. A website and database for inclusion of patients and data in this study was recently developed with support from the GBS-CIDP Foundation. We aim to include at least 1000 patients with GBS in IGOS. The grant was used to implement the study and we performed the following activities: (1) Neurologists from all over the world were approached to participate. At present (September 2013) more than 250 neurologists from 181 research centers from 18 countries are participating or preparing to participate. (2) The IGOS secretary supported these participants to obtain approval from the local Institutional Review Boards (IRB). The current state is that 106 centers have IRB approval. (3) Information sheet for patients were translated in 8 foreign languages by the participant and official translation agencies. (4) We facilitated the data entry and conducted regularly data quality controls. (5) Maintenance and updates of the IGOS website and database (see (6) Support with registration, transport and storage of the collected biomaterials. (7) Two meetings for the IGOS consortium were organized, which were held during the INC congress in Rotterdam, The Netherlands in July 2012, and during the PNS congress in Saint-Malo, France in June 2013. IGOS officially started in July 2012. At present 208 GBS patients are included from 14 countries including the UK (53 patients), USA (41 patients), Italy (25 patients), Denmark (25 patients), Netherlands (24 patients), Germany (13 patients), Spain (12 patients), Japan (6 patients), France (3 patients), Argentina (3 patients), Canada (3 patients), Belgium (1 patient), Australia (1 patient), and Malaysia (1 patient). Researchers from Bangladesh, Brazil, India and Taiwan also have shown interest to participate and are in the process of acquiring IRB approval. IGOS will result in the world’s largest prospectively collected clinical database and biobank which will be used to understand the processes that determine disease cause, progression and recovery. These insights will form the basis to accurately predict the clinical course of individual patients with GBS and to develop new strategies to personalize therapy.

Peripheral Neuropathy Outcome Measures Standardization (PeriNoms) Study; Dr. I.S.J. Merkies Universiteit Maastricht, The Netherlands

2009 Grants

Engineering chimeric protein(s) to enhance nerve repair in antibody-mediated preclinical models of autoimmune neuropathy; Prof K.A. Sheikh University of Texas, Houston, TX

We had funding for one year but spent at least 2 years on this project. Progress has been slow on this one and include generation of six different constructs of human and mouse EPO conjugated with 3 different mouse IgG Fc isotypes. We have tried to express mouse EPO constructs in a mammalian cell line and had only limited success with one construct. The level of protein expression is extremely low. Despite our best efforts, we have been able to generate sufficient chimeric protein to carry out pharmacokinetic and efficacy studies in animals. The project is currently dormant due to funding. But once funding is available we plan to have some of these chimeric proteins expressed in sf9 insect cells. I have talked with protein expression experts and they do not have any additional suggestions except trying the insect cells. Apparently, expressing chimeric proteins in mammalian systems is tedious and unpredictable hit or miss. If insect expression provides us sufficient chimeric protein then will test this in animal studies. I have asked the lab to prepare a power point containing key data showing protein generation, which is attached. All EPO-Fc constructs and transfected CHO cell lines are available as a resource for sharing.

Prognostic models for Guillain-Barré syndrome; Dr. B.C. Jacobs Erasmus MC, The Netherlands

Guillain-Barré syndrome (GBS) has a highly variable clinical course and outcome. Despite the fact that various studies described prognostic factors in GBS, these are difficult to apply in clinical practice. To support patients, family and neurologists we have developed various validated prognostic models which are based on clinical characteristics which can be easily obtained at the bedside of the patient. These models were developed to predict in individual patients with GBS the chance of respiratory failure (Walgaard et al. Brain 2010) and severe disability at one to six months (Walgaard et al. Neurology 2011). These models have found their way to the clinic and are for example used in the Dutch National Guideline for the treatment of GBS. The next step was to further improve and validate these prognostic models in a large cohort of GBS patients. Such numbers of patients can only be reached by large scale international collaboration. With support from the GBS-CIDP Foundation International we have initiated the International GBS Outcome Study (IGOS). IGOS is conducted by the members of the Inflammatory Neuropathy Consortium (INC). The aim of the IGOS is to identify the clinical and biological predictors of the clinical course and outcome of GBS. Supported by this grant a website and web based data entry system and database was developed by a professional web designer.

Schwann cell replacement therapy for chronically denervated nerves; Dr. H. C. Lehmann Heinrich-Heine University, Germany

Our project is based on the well-recognized clinical dilemma that patients with Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) often show an incomplete recovery and poor functional outcome after a prolonged, severe disease course. Previous experimental studies suggested that incomplete recovery in peripheral nerve disorders is partially attributable to morphological changes in the distal segments of chronically denervated nerves. There is evidence that Schwann cells, which provide trophic support under normal conditions, become atrophic and lose their ability to support the regeneration of axons after prolonged denervation. Thus we wanted to explore the underlying cellular mechanisms of this chronic denervation condition in GBS and CIDP. Moreover we pursue the idea that axonal regeneration within those chronic denervated nerve segments in patients with GBS and CIDP could be enhanced by transplantation of freshly extracted, healthy Schwann cells. To address this clinically important issue we adapted and modified an animal model, which mimics the situation of chronic denervation, comparable to those of GBS/CIDP patients after a prolonged disease course with secondary axonal loss. The project was started in 2010 and is still ongoing.

2008 Grants

Peripheral Neuropathy Outcome Measures Standardization (PeriNom) Study Dr. I.S.J. Merkies Universiteit Maastricht, The Netherlands

Different methods have been used to study patients with inflammatory polyneuropathies. The use of proper outcome measures is very important to facilitate adequate follow-up and evaluate treatment effects. The PeriNomS study aimed to expand the clinimetric knowledge on outcome measures at selected levels of outcome (mainly at the impairment, activity & participation, and quality of life levels) in patients with Guillain-Barré Syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN) and monoclonal gammopathy of undetermined significance related polyneuropathy (MGUSP).

Autonomic Failure and pain in Guillain-Barre Syndrome: A skin biopsy study; Prof P.A. van Doorn Erasmus MC, The Netherlands

We performed a prospective study in 32 patients with Guillain–Barré syndrome (GBS) or its variants to correlate intraepidermal nerve fiber density (IENFD) at the distal leg and lumbar region with pain, autonomic dysfunction, and outcome. In the acute phase, IENFD was reduced in 60% and 61.9% of patients at the distal leg and lumbar region, respectively. In the acute phase, 43.7% of patients complained of neuropathic pain. Their IENFD at the distal leg was significantly lower than in patients without pain (P < .001) and correlated with pain intensity (rs = [1]0.51; P = .003). Intriguingly, also patients with the pure motor variant of GBS and pain had low IENFD. At 6-month follow-up, only 3 patients complained of persisting neuropathic pain, whereas 3 patients reported late-onset pain symptoms. IENFD in the acute phase did not predict presence or intensity of pain at 6-month follow-up. IENFD in the acute phase did not correlate with clinical dysautonomia or GBS severity at nadir. However, it correlated with poorer GBS disability score at 6 months (P = .04), GBS score at nadir (P = .03), and clinically probable dysautonomia (P = .004). At 6-month follow-up, median IENFD remained significantly low both at the distal leg (P = .024) and lumbar region (P = .005). Double and triple staining confocal microscope studies showed diffuse damage of myelinated dermal nerves along with axonal degeneration, and mononuclear cell infiltration. Unmyelinated and myelinated skin nerves are diffusely affected in GBS and its variants, including the pure motor form. IENFD declines early, remains low over time, correlates with pain severity in the acute phase, and may predict long-term disability.

Database of Multifocal Motor Neuropathy and Other Inflammatory Neuropathies; Prof R.A. Lewis Wayne State University. Detroit, MI

The project was to create a registry/database of patients with Multifocal Motor Neuropathy and if successful to be utilized in the future for other inflammatory neuropathies. The funds were utilized to contract with the University of Maryland Bioinformatics Department to assist in the creation of the database, and the implementation of a web-based data entry system. A committee of neurologists active in the Inflammatory Neuropathy Consortium met at the INC meetings and dialogued by email to work on the information that would be put into the database. It was decided that the initial product would be a registry that would include demographics, whether the patient met either AANEM or EFNS criteria, whether conduction block was identified, whether there were any sensory signs or symptoms and whether GM1 antibodies were present. In addition, information on treatments used and their efficacy was included.

2007 Grants

Spontaneous Autoimmune Polyneuropathy in the NOD Mouse; Prof B. Soliven The University of Chicago, Chicago, IL

The antigen/s and the triggering mechanisms causing chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) remain elusive. B7-2 is one of the molecules expressed by antigen presenting cells and is required for optimal activation of T lymphocytes. When B7-2 is eliminated in non-obese diabetic (NOD) mice, animals do not develop diabetes, but instead they develop a spontaneous autoimmune polyneuropathy (SAP), which mimics CIDP in many ways. Funding support from the GBS/CIDP Foundation International has facilitated our efforts to identify potential target antigens in B7-2 knockout NOD mice using a combination of immunologic methods that include proliferation assay, cytokine secretion, adoptive transfer and intravenous tolerance studies. We found the myelin P0 is one of the auto-antigens involved in the development of autoimmune neuropathy in this model, and that this protein is also expressed by Schwann cells in the pancreas. These findings suggest that a subset of patients with CIDP, particularly those with increased susceptibility to develop type 1 diabetes, may be mediated by autoimmunity against myelin P0. Data from this pilot grant were included in a manuscript published in the Journal of Immunology (Kim et al., 2008), and formed the basis of a successful NIH grant application.

Neuroprotection and Enhancement of Nerve Repair with Erythropoietin in EAN; Prof K.A. Sheikh Johns Hopkins, Baltimore, MD

Erythropoietin (EPO) is a pleiotropic cytokine originally identified for its role in erythropoiesis. In addition, in various preclinical models EPO exhibited protective activity against tissue injury. There is an urgent need for potent treatments of autoimmune driven disorders of the peripheral nervous system (PNS), such as the Guillain-Barre´ syndrome (GBS), a disabling autoimmune disease associated with relevant morbidity and mortality. To test the therapeutic potential of EPO in experimental autoimmune neuritis (EAN) – an animal model of human GBS – immunological and clinical effects were investigated in a preventive and a therapeutic paradigm. Treatment with EPO reduced clinical disease severity and if given therapeutically also shortened the recovery phase of EAN. Clinical findings were mirrored by decreased inflammation within the peripheral nerve, and myelin was well maintained in treated animals. In contrast, EPO increased the number of macrophages especially in later stages of the experimental disease phase. Furthermore, the anti-inflammatory cytokine transforming growth factor (TGF)-beta was upregulated in the treated cohorts. In vitro experiments revealed less proliferation of T cells in the presence of EPO and TGF-beta was moderately induced, while the secretion of other cytokines was almost not altered by EPO. Our data suggest that EPO revealed its beneficial properties by the induction of beneficial macrophages and the modulation of the immune system towards anti-inflammatory responses in the PNS. Further studies are warranted to elaborate the clinical usefulness of EPO for treating immune-mediated neuropathies in affected patients.

Identifying Targets of Tumor Necrosis Factor Alpha (TNF-a) Signaling that Inhibit Schwann Cell (SC) Differentiation; Prof R.P. Lisak Wayne State University, Detroit, MI

We previously showed that some inflammatory cytokines, primarily interferon–gamma (IFN-­‐g) and tumor necrosis factor-­‐alpha (TNF-­‐a), which are found in the peripheral nerve of patients with GBS and CIDP, as well as in several animal models of GBS, are able to inhibit Schwann cells from expressing glycolipids associated with myelination in vitro. As part of our ongoing investigation into the relationships between inflammatory cytokines and Schwann cell biology, we have looked at the effects of both of these cytokines on Schwann cells. We are currently analyzing a very large set of data using gene array technology to determine if TNF-­‐a alters the pattern of gene expression induced by cAMP, which simulates many of the effects of axolemma on Schwann cells in vitro. The gene array studies might provide a gene discovery approach to identify potential targets for decreasing or reversing inflammation-­‐induced nerve demyelination. Although many laboratories, including our own, have shown that Schwann cells can upregulate major histocompatibility antigens (MHC) in vitro in response to inflammatory cytokines, in clinical and experimental inflammatory neuropathies, as well as in other diseases of the PNS, there is controversy over whether Schwann cells can upregulate major histocompatibility antigens or whether MHC expression is limited to infiltrating inflammatory cells. We postulated that Schwann cells in culture that are expressing myelin associated molecules, as many of them would be in a mature myelinated nerve, might be resistant to upregulation of MHC class II molecules as well as the adhesion molecule, intercellular adhesion molecule -­‐1 (ICAM-­‐1), also upregulated by cytokines. When we incubated undifferentiated Schwann cells with IFN‐g, the most potent stimulator of MHC Class II, both MHC Class II and ICAM-­‐1were up-regulated in many of the cells. However, when Schwann cells were treated with cAMP in the presence or absence of IFN‐g, we found that when Schwann cells were stimulated by cAMP to differentiate and express myelin associated molecules, they did not express MHC Class II or ICAM-­‐1. This indicates that the state of differentiation and perhaps myelination influences the response of SC to pro-stimulatory cytokines.

CXCR3 Blockade and Inflammatory Demyelinating Polyradiculoneuropathies (IDP); Dr. E.E. Ubogu Baylor College of Medicine, Houston, TX

Funds from this award, in addition to funds received from the Baylor College of Medicine New Investigator Start-Up program supported the isolation, purification and characterization of primary human endoneurial endothelial cells from sciatic nerves (1). These cells are responsible for forming the restrictive blood-nerve barrier. This work has led to the development of an in vitro blood-nerve barrier system to study molecular determinants and signaling pathways potentially relevant to pathologic leukocyte trafficking in GBS and CIDP. Using this model, we demonstrated the effect of physiological pro-inflammatory cytokine stimulus at the blood-nerve barrier and showed the importance of alpha M integrin and intercellular adhesion molecule-1 [ICAM-1] (2), providing a framework to better understand pathologic leukocyte trafficking potentially relevant to targeted therapies for AIDP. Recent preliminary data using a reliable mouse model of AIDP called severe murine experimental autoimmune neuritis (sm-EAN) shows that CXCR3 blockade using a proprietary drug called AMG487 improves the clinical manifestations of sm-EAN when giving after disease onset (3), suggesting that drugs that block specific chemokine receptors may be useful future therapy for peripheral nerve inflammatory disorders such as AIDP.

2006 Grants

Reversal of anti-ganglioside antibody mediated inhibition of nerve regeneration with erythropoietin; Prof K.A. Sheikh Johns Hopkins, Baltimore, MD

Guillain-Barre´ syndrome (GBS) is a monophasic immune neuropathic disorder in which a significant proportion of patients have incomplete recovery. The patients with incomplete recovery almost always have some degree of failure of axon regeneration and target reinnervation. Anti-ganglioside antibodies (Abs) are the most commonly recognized autoimmune markers in all forms of GBS and specific Abs are associated with the slow/poor recovery. We recently demonstrated that specific anti-ganglioside Abs inhibit axonal regeneration and nerve repair in preclinical models by activation of small GTPase RhoA and its downstream effectors. The objective of this study was to determine whether erythropoietin (EPO), a pleiotropic cytokine with neuroprotective and neurotrophic properties, enhances nerve regeneration in preclinical cell culture and animal models of autoimmune neuropathy/nerve repair generated with monoclonal and patient derived Abs. Primary neuronal cultures and a standardized sciatic crush nerve model were used to assess the efficacy of EPO in reversing inhibitory effects of anti-ganglioside Abs on nerve repair. We found that EPO completely reversed the inhibitory effects of anti-ganglioside Abs on axon regeneration in cell culture models and significantly improved nerve regeneration/repair in an animal model. Moreover, EPO-induced proregenerative effects in nerve cells are through EPO receptors and Janus kinase 2. Signal transducer and activator of transcription 5 pathway and not via early direct modulation of small GTPase RhoA. These preclinical studies indicate that EPO is a viable candidate drug to develop further for neuroprotection and enhancing nerve repair in patients with GBS.

Search for biological markers of inflammatory demyelinating polyneuropathies development and progression: analysis of patients displaying defective function of the Fas apoptotic pathway; Prof U. Dianzani University of Eastern Piedmont, Novara, Italy

Starting from the concept that the immune response in the peripheral nervous system is shut down through T-cell apoptosis, we aimed to assess whether defective T-cell apoptosis had a role in chronic inflammatory demyelinating polyneuropathy (CIDP) as shown for other autoimmune diseases, such as MS (Comi et al., 2000). We studied the Fas apoptotic pathway in patients with CIDP, Guillain-Barré syndrome (GBS), and in healthy controls, finding that CIDP patients displayed significantly higher T-cell survival to Fas-mediated apoptosis than both controls and GBS patients, whereas GBS patients and controls showed no difference. Moreover, the percentage of Fas-resistant (Fas-r) subjects, defined by the survival of more than 82% of their T cells to Fas-mediated apoptosis, was 52% in CIDP patients, 2% in controls, and 0% in GBS patients (Comi et al., 2006). The reason why we compared CIDP and GBS patients lies in the self-limiting nature of GBS as opposed to the persistent immune system activation of CIDP. Our hypothesis was that T-cell apoptosis might be a factor influencing, when effective, the self-limitation of the inflammatory process that we observed in GBS, or when defective, the disease persistence typical of CIDP. This concept was later reinforced by the finding that patients with acute-onset CIDP (a-CIDP) can be distinguished very early in the disease from patients with GBS by showing defective T-cell apoptosis.

2005 – 2007 Grants

A Pilot Randomized controlled trial of Methotrexate for Chronic Inflammatory Demyelinating Polyradiculoneuropathy RMC Trial; Prof R.A.C. Hughes Dept. of Clinical Neuroscience – Kings College London, England

The GBS/CIDP Foundation grant funded the largest trial of an immunosuppressive agent for CIDP yet performed. The results were published in the prestigious international journal Lancet Neurology [RMC Trial Group 2009]. The trial was a high quality randomized study undertaken in 25 centers in 5 European countries. It compared methotrexate with identical appearing dummy or placebo tablets in people with CIDP already taking intravenous immunoglobulin or corticosteroids. After about 16 weeks, the dose of corticosteroids or intravenous immunoglobulin was decreased by 20% every 4 weeks provided that the participants did not worsen. The primary outcome was achieving a greater than 20% reduction in the dose of corticosteroids or intravenous immunoglobulin in the last 4 weeks of the trial compared with the first 4 weeks. Fifty-nine people completed the trial. Fourteen (52%) of the 27 taking methotrexate were able to reduce their corticosteroid or intravenous immunoglobulin dose but, unexpectedly, so were 14 (44%) of the 32 taking the dummy tablets. Thus the trial did not show any benefit from taking methotrexate but it did show, against expectations, that 44% were taking more corticosteroids or intravenous immunoglobulin than they needed. This has affected the design of subsequent CIDP treatment trials and had a major effect on the management of CIDP worldwide. It has led to the recommendation of drug holidays to check the need for continued treatment.

2005 Grant

The Role of Schwann Cell Microvilli at Nodes of Ranvier and in Guillain-Barre Syndrome; Dr. M.N. Rasband University of Connecticut Health Center, Farmington, CT

Autoantibodies to gangliosides such as GM1 have been proposed to disrupt nodes of Ranvier in peripheral motor nerve fibers and lead to Guillain-Barré syndrome, an autoimmune neuropathy characterized by acute limb weakness. At the nodes in myelinated axons, voltage-gated Na+ channels are highly concentrated and facilitate rapid action potential conduction. Using a disease model caused by immunization with gangliosides, we showed that Na+ channel clusters were disrupted or disappeared at abnormally lengthened nodes concomitant with deposition of IgG and complement products at the acute phase with progressing limb weakness (Susuki et al. J Neurosci 2007). Paranodal axoglial junctions, the nodal axonal cytoskeleton, and Schwann cell microvilli, all of which stabilize Na+ channel clusters, were also disrupted. During recovery, complement deposition at nodes decreased, and Na+ channels redistributed on both sides of affected nodes. These results suggest that Na+ channel alterations occur as a consequence of complement-mediated disruption of interactions between axons and Schwann cells. Our findings support the idea that the axonal form of Guillain-Barré syndrome is a disease that specifically disrupts the nodes of Ranvier. We also showed that gangliosides themselves are highly accumulated at and near nodes, and contribute to the formation and maintenance of the nodal Na+ channel clusters. In the mutant mice lacking gangliosides including GM1, ion channel clusters and structures at and near nodes were remarkably disrupted (Susuki et al. Glia 2007). Abnormal molecular organization at paranodes became more prominent with age. Furthermore, the defects were more prevalent in ventral than dorsal roots, and less frequent in mutant mice lacking the b-series gangliosides but with excess GM1. These results indicate that gangliosides contribute to stability and maintenance of nodes of Ranvier, and further support the critical roles of anti-ganglioside antibodies in Guillain-Barré syndrome.

2004 Grants

Determination of anti-ganglioside antibody affinity in patients with GBS; Prof K.A. Sheikh, MD Johns Hopkins, Baltimore, MD

Antibody affinity and nerve injury in GBS is a complex issue. Our work points out at least 3 issues:

  1. Anti-ganglioside antibody affinity/avidity is likely not related to selective targeting, i.e., sensory vs motor nerve fiber recognition. Fine specificity of the antibodies is more relevant to this aspect. We had to clone a new anti-GD1a antibody with an order of magnitude higher affinity to make this point and also tested AMAN sera in this context. This was published in Brain 2008. See attached articles. GBS/CIDP foundation support acknowledged.
  2. Antibody affinity/avidity seems to be a factor in nerve fiber injury. This was shown with different GM1 ligands with low to extremely high affinities. In this study a monoclonal antibody with low affinity did not cause nerve injury, GBS patient anti-GM1 antibodies with moderate affinities produced nerve injury, and cholera toxin subunit B (ligand with highest affinity for GM1) produced more severe injury. This was published in J Neuroscience 2010. See attached articles. GBS/CIDP foundation support acknowledged.
  3. We also have unpublished data, which show that GBS patients have a range of affinities but the majority are in the moderate range. The antibody affinities are not as high as for example in M G. The caveat with the data are that these are cross-sectional data on antibodies in circulation. We have reason to believe that higher affinity antibodies may have shorter circulating half-lives. In order to produce injury moderate affinity antibodies must have robust Fc effector functions.   We have preliminary data that indicate that Fc functions of anti-ganglioside antibodies are critical in producing nerve inflammation and injury.

A New Approach to Treatment of the Guillain-Barre Syndrome; Prof B. Arnason, MD University of Chicago, Chicago, IL

The basic idea was that we could use a construct we had developed with interesting immunomodulatory properties to treat EAN. It did not work: we still don’t quite understand why it didn’t. It didn’t work in EAE either even while it did work in an animal model for ITP. The construct is comprised of multiple copies of the CH2 region of IgG arranged linearly with the cysteines replaced by lysines to assure an open configuration so that the construct cross links multiple copies of all 3 classes of Fc gamma receptors, both activating and inhibiting, expressed on macrophages and thereby induce an off signal for cytokine secretion. Although this particular experiment failed other attempts, in addition to the ITP study, did not. When we put an antigenic peptide on the construct, the peptide was preferentially taken up by macrophages and dendritic cells with 10-100 times the antibody production seen when antigen alone was given. We now have US, Japanese, European and Australian patents for our technology, a start-up company called Iterative Therapeutics, a wet lab in an industrial complex across town, and 2 Small Business grants (SBIRs) from the NIH. One is to use our construct to augment the efficacy of Herceptin, since our construct really activates NK cells, perhaps because they express only activating receptors, and the other is to develop a vaccine to Botulinum toxin, a vaccine of potential interest to militaries concerned about bioterrorism. Another company has licensed our technology for an anthrax vaccine that they are developing. The funded projects, should they work out, will provide proof of principle, or so we hope, since if it works in one cancer it might well work in others, and ditto for vaccines. Thus, though the EAN project failed, the concept is still alive.

Synthetic disialylgalactose immunoadsorbents deplete anti-GQ1b antibodies from autoimmune neuropathy sera; Prof. Hugh Willison Institute of Neurological Sciences, Glasgow, Scotland

Acute and chronic autoimmune neuropathies, including Guillain-Barré syndromes (GBS) are often characterized by the presence of autoantibodies that react with neural gangliosides. Evidence from human and animal studies indicates that anti-ganglioside antibodies play a primary neuropathogenic role, and their rapid elimination from the circulation through specific immunoadsorption therapy thus has the potential to ameliorate the course of the disease. Here we have tested this therapeutic principle in the Miller Fisher variant of GBS that is associated serologically with acute phase anti-GQ1b ganglioside immunoglobulin G (IgG) antibodies, and in chronic ataxic neuropathies associated with persistently elevated immunoglobulin M (IgM) antibodies that react with GQ1b, GD3 and other disialylated gangliosides. Human and mouse anti-GQ1b IgG and IgM antibodies may also react with GD3, suggesting the shared terminal disialoside epitope could be involved in antibody binding. We thus synthesized the terminal trisaccharide, NeuAc(alpha2-8)NeuAc(alpha2-3)Gal common to GQ1b and GD3, and conjugated it to bovine serum albumin (BSA). This disialylgalactose glycoconjugate (DSG-BSA) binds anti-GQ1b antibodies in 32/58 (55%) human sera containing IgG or IgM anti-GQ1b antibodies at titres up to 1/130 000; it also binds a wide range of mouse monoclonal anti-GQ1b and -GD3 antibodies. When conjugated to Sepharose as mock therapeutic immmunoaffinity columns, the immobilized trisaccharide (DSG-Sepharose) eliminates anti-GQ1b antibodies from positive sera in proportion to their level of binding to DSG-BSA. Oligosaccharide-specific immunoadsorption therapy thus provides a new therapeutic approach to anti-GQ1b antibody-associated syndromes that could be applied to clinical practice. Furthermore, modification of the immobilized oligosaccharide epitopes to incorporate other glycan structures may allow this approach to be adapted to other forms of autoimmune neuropathy associated with uniform anti-glycolipid antibody profiles.

Research News

See more Research News